Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial

By K. Chan, K. Teo, Jean G. Dumesnil, A. Ni, J. Tam. Circulation, 2010

767 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “stenosis in the absence of other indications for their use is not recommended.(266,479) 481 III A”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “100,131 Secondary targets have also been defined by inference for nonHDL-C and for apoB; they receive a moderate grading, as they have not been extensively studied in RCTs. Clinicians who are using apoB in their practice can use targets levels of <100 mg/dL and <80 mg/ dL for subjects at high or at ”
2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “AVR is reasonable in apparently asymptomatic patients with severe AS (stage C1) with (27, 38), (Level of Evidence: B): a.”
Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). (2012, unknown): “A few studies have recommended the potential use of percutaneous coronary intervention in place of CABG in patients with AS.”